TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06733077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait with cueing wearable device and neuro-ocular performance
Description: Participants will be invited to participate in the following sequential phases. Participants can participate in Phases as selected. Control participants will not be invited to Phase 4.~Phase 1. Lab testing \[2 hours\] Validation study of digital technology measures MachineMD and gaitQ to criterion metric of UPDRS.~Phase 2. home/community testing \[2 weeks daily\] Determine feasibility of daily measuring in the home of gaitQ to determine usability, acceptability, and day to day variability of measurement metrics and to determine concurrent validation of home metric to lab metrics to determine, reliability, concurrent validity of change, minimal detectable change and criterion validation to lab-based measures.~Phase 3. Lab retesting \[2 hours\] see Phase 1~Phase 4. Home/community intervention \[2 weeks\] Determine the potential for effect of the gaitQ vibration intervention from a 2-week exposure in the home.
Study: NCT06722170

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EH002 administration
Description: EH002 was administered into one or both ears via intracochlear injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EH002 administration
Description: EH002 was administered into one or both ears via intracochlear injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EH002 administration
Description: EH002 was administered into one or both ears via intracochlear injection.
Study: NCT06732193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-site respiratory physiotherapy
Description: The patient attends face-to-face physiotherapy sessions prescribed by the doctor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On-site respiratory physiotherapy
Description: The patient attends face-to-face physiotherapy sessions prescribed by the doctor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fissios App
Description: The patient uses the Fissios App to perform respiratory physiotherapy exercises.
Study: NCT06732154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5632
Description: HRS-5632 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride injection
Study: NCT06732895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
Study: NCT06723834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric Service Dog
Description: Partnership with a trained service dog for PTSD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: 12 weeks of Prolonged Exposure once per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: 12 weeks of Prolonged Exposure once per week.
Study: NCT06750705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PechaKucha
Description: The PechaKucha format consists of 20 slides, each displayed for 20 seconds, focusing on vital signs measurement skills. The method emphasizes a fast-paced, engaging, and visual learning experience designed to enhance retention and improve students' practical knowledge and skills in measuring vital signs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PowerPoint
Description: The PowerPoint presentation will cover the same vital signs measurement content but in a more conventional, linear format. The intervention will aim to reinforce students' understanding of vital signs through text and images, with a slower pace compared to the PechaKucha method.
Study: NCT06753448

Intervention type: DRUG
Intervention: Diosmin and Hesperidin Combination
Description: Participants will take diosmin and hesperidin combination for 14 days after total knee replacement surgery.
Study: NCT06751836

Intervention type: OTHER
Intervention: Infection and no infection
Description: No intervention apart from the dengue infection

Intervention type: OTHER
Intervention: Infection and no infection
Description: No intervention apart from the dengue infection

Intervention type: OTHER
Intervention: Infection and no infection
Description: No intervention apart from the dengue infection
Study: NCT06753864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T)
Description: Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T)
Description: Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.
Study: NCT05486533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The experimental group will start with LI4 points and continue P6 and LI11 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
Study: NCT06753864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R)
Description: Abaloparatide injection (Tymlos®), specification :3120 μg/1.56 ml(2000 μg/ml), drug information is subject to actual supply, provided by Qilu Pharmaceutical Co., LTD. The reference preparations for the subjects were all from the same batch number.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R)
Description: Abaloparatide injection (Tymlos®), specification :3120 μg/1.56 ml(2000 μg/ml), drug information is subject to actual supply, provided by Qilu Pharmaceutical Co., LTD. The reference preparations for the subjects were all from the same batch number.
Study: NCT06754384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)
Description: Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
Description: Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
Description: High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
Description: EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for ages 6-12 years)
Description: placebo (for ages 6-12 years)
Study: NCT06756126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 subcutaneous injection
Study: NCT06754683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8 weeks Self-compassion based psycho-education
Description: The Self-compassion psychoeducational intervention will be utilized as the intervention in this study will be delivered by the first investigator and supervised by the Principal investigator, who has experience in mindfulness and self-compassion practices. It will consist of eight weekly 1.5 hours of face-to-face sessions and 1 hour each week of online sessions. Each session will be according to a specific topic that will cover the objectives of the study, incorporating the concept of self-compassion interventions based on the research literature and input from experts in the field, taking into consideration the needs of the participants. Participants will be required to have at least 80% of attendance for intervention completion.
Study: NCT06752876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-010
Description: CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-010
Description: CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
Study: NCT06753682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Plant Based Diet
Description: Registered Dietician will assist in modifying the patient's diet
Study: NCT06753487

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofacial Release
Description: Manual Myofascial Release:~Control group will receive 3- 5 repetitions of Manual Myofascial Release in Piriformis muscle i.e giving ischemic pressure on muscle directly for 90 secs and then release.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facilitated positional release technique
Description: FPRT:~Treatment group will receive 5 repetitions of FACILITATED POSITIONAL RELEASE technique i.e applying pressure over tender area of muscle while maintaining specific postion
Study: NCT06751849

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-loaded DC vaccine
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06269393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBI311
Description: IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
Study: NCT05131373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORG101 - Experimental 1
Description: C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ORG101PL - Placebo 1
Description: Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
Study: NCT06753110

Intervention type: DEVICE
Group type: OTHER
Intervention: OPRA transhumeral
Description: Skeletal anchorage of amputation prostheses.
Study: NCT06754124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Group
Description: Pilates training will be given individually for approximately 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all participants will be taught the basic elements of Pilates in 1 session. Pilates training will begin with standing exercises for warming up and centering in the supine position. Training will continue with upper and lower extremity movements. The intensity of the exercises will be increased by using different positions and elastic bands. Stretching exercises and posture exercises will be used during the cool-down period. All exercises will start with 10 repetitions and will be increased to 20 later. Each movement will be shown by the physiotherapist first so that the patients can do the movements correctly. The movements that the patients cannot do will be modified appropriately and applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No exercise will be allowed for 8 weeks and routine medication will continue.
Study: NCT04711889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Ulinastatin is taken three times a day.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Blank control
Description: Blank control
Study: NCT04648189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
Study: NCT04649866

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: plethysmography
Description: Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: plethysmography
Description: Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline
Study: NCT06487455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH7485
Description: SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
Study: NCT05974449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Lactobacillus capsules
Description: This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Lactobacillus capsules
Description: This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
Study: NCT04840550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15 mg
Description: Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 25 mg
Description: Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Study: NCT05884346

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrahigh-frequency ultrasound
Description: Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrahigh-frequency ultrasound
Description: Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
Study: NCT05741879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified exercise training
Description: Participants will complete a 2-days-a-week online training routine with their families: Each session will include a Warm-Up/Activation phase (3 minutes: light intensity continuous training), a Training phase (10-26 minutes: 6-12 repetitions, 20-40 of work, 10-20 recovery), and a Cool Down phase (3 minutes: static and dynamic exercises). The exercises will be different each week and will increase in length and intensity accordingly. The sessions will be supervised by the participants parent(s) and/or guardian(s).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: This group will be allocated to standard care and therefore no gamified online exercise training will be provided. They will continue to perform their daily routine/activities including their basic motor skills classes at school and their extracurricular sports and/or cultural activities.
Study: NCT05498441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotics, mood stabilizers, etc.
Description: During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotics, mood stabilizers, etc.
Description: During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
Study: NCT05912296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD7022
Description: Subcutaneously Administered RBD7022 in Healthy Subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD7022
Description: Subcutaneously Administered RBD7022 in Healthy Subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo in Healthys Subject.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo in Healthys Subject.
Study: NCT05240105

Intervention type: OTHER
Intervention: no intervention, purely observational
Description: There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.

Intervention type: OTHER
Intervention: no intervention, purely observational
Description: There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.

Intervention type: OTHER
Intervention: no intervention, purely observational
Description: There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.

Intervention type: OTHER
Intervention: no intervention, purely observational
Description: There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.
Study: NCT05042778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Description: A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
Study: NCT05653219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Concentrate for solution for infusion for intravenous use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Concentrate for solution for infusion for intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eltrombopag
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concentrate for solution for infusion for intravenous use.
Study: NCT04937153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously (IV) once every 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously (IV) once every 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV once every 21 days.